PHGE BiomX Inc. Insider Trading

Director Yeganeh Reuven sold 980,000 shares (980.0K) for $4,900,000.00 at $5.00 across 2 trades, reducing holdings to 0 shares from derivative conversion.

Yeganeh Reuven sold 450,000 shares at $5.00 on 2026-03-16 and 530,000 shares at $5.00 on 2026-03-17, totaling 980,000 shares for $4,900,000.00 at a blended average price of $5.00. The Form 4 filing indicates a derivative-conversion transaction, meaning these shares represent the conversion of derivative securities into common stock and their immediate or near-term sale, not a simple open-market position exit. The stock is now trading at $5.04, only +0.8% above the sale price, while down -59.2% from its 52-week high of $12.35. The company is unprofitable with a net loss of $-9,166,000.00 over its most recent full fiscal year and carries a market cap of $8,032,263.12. The director's prior two trades at PHGE on 2026-03-12 and 2026-03-13 (also sales) have outcomes not yet measurable. This filing requires attention to the Form 4 Table II derivative securities details to assess the insider's total beneficial position, as Table I alone does not capture the complete holdings picture.

Director Yeganeh Reuven sold 670,000 shares (670.0K shares) for $3,350,000.00 in 2 transactions at $5.00

Yeganeh Reuven, a director at BiomX Inc. (PHGE), executed 2 separate sales totaling 670,000 shares for $3,350,000.00 on March 12–13, 2026 at a blended average price of $5.00. The company is unprofitable with net income of $-9,166,000.00 over its most recent full fiscal year, and the current stock price of $6.19 stands 49.9% below the 52-week high of $12.35 but 10.0% above its 30-day average. This transaction involved derivative securities conversion (Form 4 Table II), meaning the director's actual position extends beyond the Table I shares_after figure of zero, and therefore should not be characterized as a complete exit. The sale occurred at a discount to the current market price, representing a liquidation of a specific batch of shares rather than a position restructuring in the context of company financial distress.